Temasek Life Sciences Accelerator

Temasek Life Sciences Accelerator
Name	Temasek Life Sciences Accelerator
Formation	2003
Founder	Temasek Holdings
Type	Research accelerator
Headquarters	Singapore
Location	Biopolis
Leader title	CEO

Temasek Life Sciences Accelerator is a Singapore-based translational biomedical research accelerator focused on advancing life sciences innovations from discovery toward commercialization. It serves as a bridge between basic research institutions, biotechnology startups, and industry partners, fostering translational projects in areas such as therapeutics, diagnostics, and agriculture biotechnology. The accelerator operates within an ecosystem that includes prominent research institutes, universities, and investment entities in Singapore and the wider Asia region.

Overview

The accelerator functions as an incubator and translational vehicle linking institutions such as National University of Singapore, Nanyang Technological University, Agency for Science, Technology and Research, Duke–NUS Medical School, and A*STAR research institutes with private-sector partners including Temasek Holdings, venture capital firms, and multinational corporations. It emphasizes multidisciplinary teams drawn from institutions like Massachusetts Institute of Technology, Stanford University, Harvard University, University of Cambridge, and University of Oxford to translate discoveries into products and companies. The model mirrors aspects of accelerators such as Y Combinator, Biotechnology Innovation Organization, and Cambridge Enterprise while operating within the biomedical infrastructure of Biopolis, One North, and regional innovation hubs like Shinagawa and Shenzhen.

History and Development

Founded in 2003 with endowment and strategic backing from Temasek Holdings, the accelerator evolved alongside development initiatives in Singapore including the creation of Biopolis and expansion of translational research through A*STAR and university biomedical campuses. Early collaborations involved technology transfer partnerships with entities such as Genentech, GlaxoSmithKline, Novartis, and Roche while academic links included Imperial College London, Johns Hopkins University, and Cold Spring Harbor Laboratory. Over time, the accelerator adopted practices influenced by entrepreneurial ecosystems exemplified by Silicon Valley, Cambridge (UK), and Israel’s Yozma program, broadening its remit to include agricultural biotechnology and synthetic biology in partnership with organizations like DuPont and Syngenta.

Research Programs and Focus Areas

Programs concentrate on translational pipelines in areas such as drug discovery, molecular diagnostics, cell therapy, and precision agriculture. Research themes intersect with targets and technologies from leading programs at Broad Institute, Sanger Institute, Wellcome Trust, Bill & Melinda Gates Foundation, and Cancer Research UK. Projects often leverage platforms including CRISPR-based gene editing pioneered at institutions such as University of California, Berkeley, MIT, and Harvard Medical School; single-cell genomics approaches developed at Broad Institute and Sanger Institute; and bioinformatics methods associated with European Bioinformatics Institute and National Institutes of Health. Collaboration networks extend to clinical partners like Singapore General Hospital, KK Women's and Children's Hospital, and international hospitals such as Mayo Clinic and Cleveland Clinic.

Facilities and Infrastructure

Facilities are housed in research clusters near Biopolis and One North, offering wet labs, translational pilot plants, high-throughput screening suites, and BSL-2/3 containment options. Core infrastructure reflects standards used by Harvard Medical School core facilities, Max Planck Society institutes, and European Molecular Biology Laboratory centers, with access to proteomics platforms akin to those at Proteomics Institute sites. Shared resources include high-content imaging, flow cytometry, next-generation sequencing sequencers comparable to Illumina deployments, and bioprocessing suites modeled after industrial partners like Thermo Fisher Scientific and GE Healthcare Life Sciences.

Funding, Partnerships, and Governance

Funding originates from Temasek Holdings endowments, competitive grants linked to Ministry of Health (Singapore), translational funds associated with Economic Development Board (Singapore), and co-investment from venture firms and corporate partners. Governance structures incorporate advisory boards with representatives from National Research Foundation (Singapore), academic leaders from Yale-NUS College, and industry executives from Pfizer, Johnson & Johnson, and Merck & Co.. The governance model draws on best practices from Wellcome Trust governance, Bill & Melinda Gates Foundation program oversight, and corporate governance frameworks used by Temasek Holdings itself.

Notable Projects and Achievements

Achievements include spinning out translational ventures that partnered with multinational companies for licensing and development, and advancing diagnostic platforms into clinical validation phases with partners like Roche Diagnostics and Abbott Laboratories. Projects have created links to global consortia such as the Human Cell Atlas, International Cancer Genome Consortium, and Global Alliance for Genomics and Health. The accelerator has supported discovery-stage therapeutics that entered preclinical development, leveraging target validation approaches from laboratories associated with Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

Training, Outreach, and Industry Collaboration

Training programs offer entrepreneurship workshops, regulatory affairs seminars, and clinical trial design modules involving experts from U.S. Food and Drug Administration, European Medicines Agency, and regional regulatory agencies. Outreach connects researchers to investors from firms like Sequoia Capital, SoftBank, Temasek Capital, and corporate venture groups from Novartis Venture Fund and Pfizer Ventures. Industry collaborations include co-development agreements with Bayer, Takeda Pharmaceutical Company, and agritech partnerships with Corteva and BASF. The accelerator also engages in public-private dialogues alongside entities such as World Health Organization and Asian Development Bank to align translational priorities.

Category:Research institutes in Singapore